Imprint Wealth LLC Takes Position in IQVIA Holdings Inc. (NYSE:IQV)

Imprint Wealth LLC bought a new stake in IQVIA Holdings Inc. (NYSE:IQV) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 131,737 shares of the medical research company’s stock, valued at approximately $13,174,000. Imprint Wealth LLC owned approximately 0.07% of IQVIA at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of IQV. Mutual Advisors LLC increased its holdings in shares of IQVIA by 3.1% during the second quarter. Mutual Advisors LLC now owns 1,602 shares of the medical research company’s stock worth $360,000 after purchasing an additional 48 shares during the period. Parkside Financial Bank & Trust lifted its stake in shares of IQVIA by 19.6% in the second quarter. Parkside Financial Bank & Trust now owns 293 shares of the medical research company’s stock worth $66,000 after acquiring an additional 48 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its stake in shares of IQVIA by 1.1% in the 2nd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 5,034 shares of the medical research company’s stock valued at $1,131,000 after purchasing an additional 55 shares during the last quarter. Byrne Asset Management LLC grew its holdings in IQVIA by 0.8% during the 2nd quarter. Byrne Asset Management LLC now owns 6,709 shares of the medical research company’s stock worth $1,508,000 after acquiring an additional 56 shares during the period. Finally, Penserra Capital Management LLC lifted its stake in IQVIA by 6.1% in the fourth quarter. Penserra Capital Management LLC now owns 971 shares of the medical research company’s stock valued at $198,000 after buying an additional 56 shares during the period. 86.82% of the stock is owned by institutional investors.

IQVIA Price Performance

Shares of IQVIA stock traded up $1.36 during trading hours on Monday, reaching $206.15. 850,109 shares of the company’s stock were exchanged, compared to its average volume of 1,096,962. The company has a market capitalization of $37.62 billion, a P/E ratio of 34.42, a price-to-earnings-growth ratio of 2.64 and a beta of 1.42. The company has a quick ratio of 0.79, a current ratio of 0.79 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a 1 year low of $167.42 and a 1 year high of $241.86. The business has a fifty day moving average of $197.42 and a two-hundred day moving average of $207.40.

Insider Activity

In other news, insider Constantinos Panagos sold 27,317 shares of IQVIA stock in a transaction on Tuesday, September 19th. The stock was sold at an average price of $208.67, for a total value of $5,700,238.39. Following the completion of the sale, the insider now directly owns 14,250 shares of the company’s stock, valued at $2,973,547.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 1.50% of the company’s stock.

Wall Street Analysts Forecast Growth

IQV has been the subject of a number of analyst reports. Stifel Nicolaus lifted their price target on IQVIA from $255.00 to $281.00 and gave the company a “buy” rating in a research note on Wednesday, August 2nd. Mizuho lowered their target price on shares of IQVIA from $250.00 to $229.00 and set a “buy” rating on the stock in a report on Tuesday, October 10th. HSBC initiated coverage on shares of IQVIA in a research note on Wednesday, September 6th. They set a “buy” rating and a $260.00 price objective for the company. Citigroup lifted their price target on IQVIA from $200.00 to $225.00 and gave the company a “neutral” rating in a research report on Wednesday, August 2nd. Finally, Truist Financial cut their target price on shares of IQVIA from $260.00 to $240.00 and set a “buy” rating for the company in a research report on Friday, November 3rd. Three analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $236.57.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.